The latest cancer drugs news
Browsing: Cancer Drug News
Scientists call into question safety of potential new anticancer treatment
Scientists have discovered that a promising new anticancer medicine currently in development could be made…
Scientific breakthrough: We can now halve the price of costly cancer drug
Taxol is one of the most commonly prescribed chemotherapy drugs for breast, ovarian, cervical and…
Daratumumab may help cancer patients with low physical function to live longer, study finds
How cancer patients relying on daratumab feel physically before starting the therapy can predict how long…
Nivolumab subcutaneous formulation given approval across multiple solid tumour types in the UK
Bristol Myers Squibb (BMS) has announced that the UK Medicines and Healthcare products Regulatory Agency…
New study highlights success of Financial Toxicity Tumour Board in reducing cancer treatment costs
Financial toxicity, the financial distress linked to cancer treatment, significantly impacts patient outcomes. To combat…
FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx with cisplatin or carboplatin…
NICE approves dual immunotherapy for the first line treatment of adult patients with mismatch repair deficient or microsatellite instability high unresectable or metastatic colorectal cancer approved in the UK
Nivolumab in combination with ipilimumab has been granted an indication extension in the UK by…
Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: Hint of major added benefit
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes…
How oncologists respond to negative trials
FDA Withdrawals and Oncology Drug Use The U.S. Food and Drug Administration’s (FDA) accelerated approval…
FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for…